Daniel Faga - 12 May 2026 Form 4 Insider Report for First Tracks Biotherapeutics, Inc. (TRAX)

Reporting relationship: President, CEO, Director
Issuer ticker: TRAX
Reported as of: 12 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 May 2026, 16:05:11 UTC
Prior SEC filing: 23 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Ajim Tamboli, Attorney-in-Fact

Key filing fact

Daniel Faga filed Form 4 for First Tracks Biotherapeutics, Inc. (TRAX) on 14 May 2026.

Key facts

This page summarizes Daniel Faga's Form 4 filing for First Tracks Biotherapeutics, Inc. (TRAX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 14 May 2026, 16:05.

Change

Previous filing in this sequence was filed on 23 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001673528 Primary reporting owner

Faga Daniel

Relationship: President, CEO, Director
Address: 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO
Signature: /s/ Ajim Tamboli, Attorney-in-Fact
Signature date: 14 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TRAX transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +100,200
Change %
Price: $0.000000^*
Shares after: 100,200
Date: 12 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,200
Exercise price
Footnotes: F1, F2

TRAX transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +271,100
Change %
Price: $0.000000^*
Shares after: 271,100
Date: 12 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 271,100
Exercise price: $17.81
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

Footnote F2

The RSUs vests as to 25% of the total RSUs annually commencing on May 12, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F3

The stock option vests as to 25% of the total shares on May 12, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F4

In addition to the options to purchase a total of 271,100 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 1,035,941 shares of common stock, which options vest according to their terms.